Evidence map›Paper›PMID 40615453›Full record

ArticleScientific reports2025

Clinical profile, treatment, and outcomes of febrile neutropenia in hematologic disorders: a look at 30-day mortality predictors.

Eskedar Ferdu Azerefegne, Gebeyehu Tessema Azibte, Fitsum Seyoum Bekele, Kehabtimer Shiferaw Kotiso, Berhanu Moges Abera, Bereket Abraha Molla, Yonatan Habtamu Tamene, Wondwossen Amogne Degu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eskedar Ferdu AzerefegneDivision of Infectious Diseases and HIV Medicine, Department of Internal Medicine, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia.
Gebeyehu Tessema AzibteDepartment of Internal Medicine, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia. gebe10tessema@gmail.com.
Fitsum Seyoum BekeleDepartment of Radiology, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia.
Kehabtimer Shiferaw KotisoSchool of Public Health, college of medicine and health sciences, Werabe University, Werabe, Ethiopia.
Berhanu Moges AberaDepartment of Internal Medicine, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia.
Bereket Abraha MollaDepartment of Internal Medicine, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia.
Yonatan Habtamu TameneDepartment of Internal Medicine, college of medicine and health sciences, Addis Ababa university, Addis Ababa, Ethiopia.
Wondwossen Amogne DeguHonorary Professor of Molecular and Clinical Medicine, Division of Infectious Diseases and HIV Medicine, Department of Internal Medicine, University of Dundee, Fellow of Ethiopian Academy of Science, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hematologic malignancies are susceptible to neutropenic fever, a potentially life-threatening condition. This study investigated the association between clinical profiles, treatment, and outcomes in these patients. A retrospective analysis of 132 patients with first-time neutropenic fever and hematologic malignancy diagnosed at Tikur Anbessa Specialized Hospital, Ethiopia, between 2019-01-01 and 2019-12-31 was conducted. Data on demographics, underlying malignancy, presumed infection site, treatment, and 30-day mortality were collected. ale predominance (13:10) was observed. Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) were the most common malignancies (43.2% and 40.9%, respectively). Chest focus of infection was the most frequent primary source (33%). Cefepime and Vancomycin combination therapy was used in 40.9% of patients. Prior febrile neutropenia and medical ICU admission during treatment significantly increased the odds of 30-day mortality (adjusted odds ratio 3.8 and 5.4, respectively). This study highlights the crucial role of prior febrile neutropenia and medical ICU admission in predicting mortality within 30 days of neutropenic fever diagnosis in patients with hematologic malignancies.

Indexed as

Febrile NeutropeniaHematologic NeoplasmsAdolescentAdultAgedAnti-Bacterial AgentsCefepimeEthiopiaFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesTreatment OutcomeAnti-Bacterial AgentsCefepimeVancomycinALLAll-cause mortalityAMLFebrile neutropenia

Identifiers

PMID40615453
PMCPMC12227762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.